Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Mutation Research
|
February 26, 2008
What histone code for DNA repair?
Alexandre E Escargueil, Daniele Grazziotin Soares, Mirian Salvador, et al.
Biochemical Pharmacology
|
May 26, 2005
Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways
Daniele Grazziotin Soares, Nadine Paese Poletto, Diego Bonatto, et al.
Journal of Cell Science
|
April 5, 2008
Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells
Alexandre E Escargueil, Virginie Poindessous, Daniele Grazziotin Soares, et al.
American Journal of Clinical Oncology
|
June 3, 2021
High-dose Chemotherapy in Germ Cell Cancer Patients With Brain Metastases: Experience of an Expert Center
Matthieu Delaye, Marc-Antoine Benderra, Louise Deforceville, et al.
Bulletin Du Cancer
|
September 24, 2018
[Metastatic stomach cancer: Clinical trials in Asia and in Occident]
Quang-Loc Bui, Daniele Grazziotin-Soares, Rodrigue E Hasiniatsy, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 28, 2007
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743
Daniele Grazziotin Soares, Alexandre E Escargueil, Virginie Poindessous, et al.
Gynecologic Oncology
|
November 19, 2022
Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trial
Benoit You, Pierre-Adrien Bolze, Jean-Pierre Lotz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2020
Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial
Benoit You, Pierre-Adrien Bolze, Jean-Pierre Lotz, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Mutation Research
|
February 26, 2008
What histone code for DNA repair?
Alexandre E Escargueil, Daniele Grazziotin Soares, Mirian Salvador, et al.
Biochemical Pharmacology
|
May 26, 2005
Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways
Daniele Grazziotin Soares, Nadine Paese Poletto, Diego Bonatto, et al.
Journal of Cell Science
|
April 5, 2008
Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells
Alexandre E Escargueil, Virginie Poindessous, Daniele Grazziotin Soares, et al.
American Journal of Clinical Oncology
|
June 3, 2021
High-dose Chemotherapy in Germ Cell Cancer Patients With Brain Metastases: Experience of an Expert Center
Matthieu Delaye, Marc-Antoine Benderra, Louise Deforceville, et al.
Bulletin Du Cancer
|
September 24, 2018
[Metastatic stomach cancer: Clinical trials in Asia and in Occident]
Quang-Loc Bui, Daniele Grazziotin-Soares, Rodrigue E Hasiniatsy, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 28, 2007
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743
Daniele Grazziotin Soares, Alexandre E Escargueil, Virginie Poindessous, et al.
Gynecologic Oncology
|
November 19, 2022
Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trial
Benoit You, Pierre-Adrien Bolze, Jean-Pierre Lotz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2020
Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial
Benoit You, Pierre-Adrien Bolze, Jean-Pierre Lotz, et al.
Page
of 1